Pretreatment multiparametric MRI is independently associated with biochemical outcome in men treated with radiation therapy for prostate cancer

Risk-stratification for localized prostate cancer remains challenging, in part due to the heterogeneous nature of the disease [1]. Determining the optimal treatment course for an individual patient requires accurate staging and appropriate risk-stratification to balance treatment efficacy with unwanted side effects. Traditional clinical risk features such as Gleason score, prostate-specific antigen (PSA) level, and clinical stage aid in this process, however significant variability in prognosis remains.
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Tags: Original Article Source Type: research